Logo image of CARM

CARISMA THERAPEUTICS INC (CARM) Stock Fundamental Analysis

NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD

0.401  -0.01 (-2.2%)

Premarket: 0.401 0 (0%)

Fundamental Rating

2

CARM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. CARM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CARM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CARM has reported negative net income.
CARM had a negative operating cash flow in the past year.
In the past 5 years CARM always reported negative net income.
CARM had negative operating cash flow in 4 of the past 5 years.
CARM Yearly Net Income VS EBIT VS OCF VS FCFCARM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

CARM has a worse Return On Assets (-151.70%) than 85.54% of its industry peers.
Industry RankSector Rank
ROA -151.7%
ROE N/A
ROIC N/A
ROA(3y)-35.89%
ROA(5y)-44%
ROE(3y)-113.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARM Yearly ROA, ROE, ROICCARM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

CARM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARM Yearly Profit, Operating, Gross MarginsCARM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

2

2. Health

2.1 Basic Checks

CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CARM has been increased compared to 1 year ago.
CARM has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CARM has a worse debt to assets ratio.
CARM Yearly Shares OutstandingCARM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
CARM Yearly Total Debt VS Total AssetsCARM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -13.48, we must say that CARM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CARM (-13.48) is worse than 80.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.48
ROIC/WACCN/A
WACC10.8%
CARM Yearly LT Debt VS Equity VS FCFCARM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

CARM has a Current Ratio of 3.23. This indicates that CARM is financially healthy and has no problem in meeting its short term obligations.
CARM has a worse Current ratio (3.23) than 62.68% of its industry peers.
CARM has a Quick Ratio of 3.23. This indicates that CARM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.23, CARM is doing worse than 60.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.23
Quick Ratio 3.23
CARM Yearly Current Assets VS Current LiabilitesCARM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.40% over the past year.
CARM shows a strong growth in Revenue. In the last year, the Revenue has grown by 90.67%.
The Revenue has been growing by 9.90% on average over the past years. This is quite good.
EPS 1Y (TTM)58.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
Revenue 1Y (TTM)90.67%
Revenue growth 3Y9.9%
Revenue growth 5YN/A
Sales Q2Q%-11.55%

3.2 Future

CARM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.56% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y64.73%
EPS Next 2Y34.8%
EPS Next 3Y22.83%
EPS Next 5Y13.56%
Revenue Next Year58.08%
Revenue Next 2Y22.51%
Revenue Next 3Y-9.61%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CARM Yearly Revenue VS EstimatesCARM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0 0 0 0
CARM Yearly EPS VS EstimatesCARM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CARM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARM Price Earnings VS Forward Price EarningsCARM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARM Per share dataCARM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CARM's earnings are expected to grow with 22.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.8%
EPS Next 3Y22.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARISMA THERAPEUTICS INC

NASDAQ:CARM (2/28/2025, 8:00:01 PM)

Premarket: 0.401 0 (0%)

0.401

-0.01 (-2.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners33.66%
Inst Owner Change17.64%
Ins Owners1.19%
Ins Owner Change0%
Market Cap16.74M
Analysts76
Price Target6.63 (1553.37%)
Short Float %2.4%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.93%
Min EPS beat(2)-16.89%
Max EPS beat(2)11.02%
EPS beat(4)2
Avg EPS beat(4)-0.6%
Min EPS beat(4)-16.89%
Max EPS beat(4)11.02%
EPS beat(8)5
Avg EPS beat(8)-2.8%
EPS beat(12)8
Avg EPS beat(12)36.08%
EPS beat(16)9
Avg EPS beat(16)34.77%
Revenue beat(2)1
Avg Revenue beat(2)45.2%
Min Revenue beat(2)-39.29%
Max Revenue beat(2)129.7%
Revenue beat(4)2
Avg Revenue beat(4)27.77%
Min Revenue beat(4)-39.29%
Max Revenue beat(4)129.7%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.5%
EPS NY rev (1m)0%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.83
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS0.49
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -151.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.89%
ROA(5y)-44%
ROE(3y)-113.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.14%
Cap/Sales 3.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.23
Quick Ratio 3.23
Altman-Z -13.48
F-Score3
WACC10.8%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
EPS Next Y64.73%
EPS Next 2Y34.8%
EPS Next 3Y22.83%
EPS Next 5Y13.56%
Revenue 1Y (TTM)90.67%
Revenue growth 3Y9.9%
Revenue growth 5YN/A
Sales Q2Q%-11.55%
Revenue Next Year58.08%
Revenue Next 2Y22.51%
Revenue Next 3Y-9.61%
Revenue Next 5Y-14.87%
EBIT growth 1Y10.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-811.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-804.08%
OCF growth 3YN/A
OCF growth 5YN/A